Conference Correspondent

Neuroendocrine tumors are highly vascular, expressing vascular endothelial growth factor (VEGF) and demonstrating angiogenesis. Since the mTOR inhibitor everolimus has antiangiogenic activity, RADIANT-3 investigators evaluated several VEGF pathway tumor markers for their prognostic and predictive potential. The results were presented by James C. Yao, MD, in an abstract presentation at ESMO.1

Oncology experts from all over the globe arrived in Vienna, Austria, to attend the Euro­pean Society for Medical Oncology (ESMO) 2012 Congress. Attendance broke all records, with 16,394 delegates, many of them from outside of Europe: 1116 from the United States, 539 from Japan, 479 from China, 292 from Argentina, and 258 from Brazil. Following are some highlights from the Presidential Symposia and papers proffered at the meeting.
The American Society for Radiation Oncology (ASTRO) 54th Annual Meeting, held in Boston, Massachusetts, coincided with Superstorm Sandy. Despite the havoc wreaked by the storm, Boston was largely spared, although ASTRO canceled Monday afternoon’s Plenary Session when public transportation was shut down.
Sildenafil is often used by men treated with radiation or radical prostatectomy for prostate cancer to achieve an erection sufficient for sexual intercourse, and it is effective to varying degrees when used on an as-needed basis.
Doxepin, a tricyclic antidepressant approved for the treatment of depression and anxiety, as well as moderate pruritus, significantly improved oral mucositis pain in patients treated with radiation therapy for head and neck cancer in a phase 3 trial.
Radiation therapy extends life in older women with early breast cancer, according to 2 different studies presented at the ASTRO 54th Annual Meeting.
Many patients with incurable lung cancer mistakenly believe that radiation therapy administered for palliative treatment of pain and other cancer symptoms represents a potential cure, according to a study presented at the ASTRO 54th Annual Meeting.
The American Society of Clin­ical Oncology 2012 Breast Can­cer Symposium, held September 13-15 in San Francisco, California, offered all members of the cancer team an upfront view of new data and an opportunity for one-on-one interaction with experts in the field. The following are a few re­search items of interest to oncology nurses.
Oncology experts from all over the globe arrived in Vienna, Austria, to attend the Euro­pean Society for Medical Oncology (ESMO) 2012 Congress. Attendance broke all records, with 16,394 delegates, many of them from outside of Europe: 1116 from the United States, 539 from Japan, 479 from China, 292 from Argentina, and 258 from Brazil.
Single-agent doxorubicin remains the standard of care as first-line treatment for unresectable or metastatic soft tissue sarcomas, according to results of a phase 3 trial conducted by EORTC and presented at the Presidential Symposium during the ESMO 2012 Congress (Abstract LBA7).
Page 29 of 41
Results 281 - 290 of 407